#### Reference

Atalar, H., Gunay, C., Komurcu, M.

Department of Orthopaedic Surgery and Traumatology, Gazi University School of Medicine, Ankara, Turkey.

# Functional treatment of developmental hip dysplasia with the Tübingen hip flexion splint

Hip International 2014, 24 (3): 295-301.

DOI: 10.5301/hipint.5000128.

#### **Products**

### Tübingen hip flexion splint


### **Major Findings**

With Tübingen hip flexion splint:

# → 93% of the examined hips were successfully treated

(Graf type 1 and no acetabular dysplasia)

Amount of successful treatment of hip dysplasia with the Tübingen hip flexion splint



### **Population**

Subjects:

49 children with 60 hips requiring treatment


45 female, 4 male

Inclusion criteria:

diagnosis of hip dysplasia

# **Study Design**

## Retrospective study:



Hip maturity was assessed after 3 to 4 weeks of wearing the orthosis. If an improvement in hip maturity was observed treatment was continued with regular follow-ups. After acetabular maturation the weaning period was started where the splint was removed for a specific (growing) period of time per day.

#### **Results**

Functions and Activ	vities					Participation
Biomechanics – Static measures		X-Ray	EMG	Functional tests	Clinical effects	Satisfaction

Category	Outcomes	Results for Tübingen hip flexion splint	Sig.*	
Clinical effects	Classification of Graf	93.3% of hips were successfully treated		
		6.7% of hips could not be treated successfully	n.a.	
		Successfully treated hips did not differ from unsuccessfully treated hips with respect to initial hip stability findings (stable vs. others), Graf type (type 2b vs. others) or number of hips involved (bilateral vs. unilateral)	0	
	Median age at start of therapy  Median duration of treatment (without weaning period)	18 weeks		
		Successfully treated hips did not differ from unsuccessfully treated hips with respect to age at start of treatment	0	
		8 weeks	n.a.	
	Median duration of weaning period	8 weeks	n.a.	
	Median total treatment time	17 weeks	n.a.	
	Median duration of follow up	13.5 months	n.a.	
	No avascular necrosis, femoral nerve dysfunction or skin lesions related to the splint were observed			

<sup>\*</sup> no difference (0), positive trend (+), negative trend (-), significant (++/--), not applicable (n.a.)

#### **Author's Conclusion**

"The Tübingen splint provides abduction, but due to its different design it offers the advantages of preventing hip adduction and leaving the knee and ankle joints free. Our findings suggest that in infants with DDH, the Tübingen hip flexion splint is an effective form of treatment." (Atalar et al. 2014)

© 2014, Otto Bock HealthCare Products GmbH ("Otto Bock"), All Rights Reserved. This article contains copyrighted material. Wherever possible we give full recognition to the authors. We believe this constitutes a 'fair use' of any such copyrighted material according to Title 17 U.S.C. Section 107 of US Copyright Law. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner. All trademarks, copyrights, or other intellectual property used or referenced herein are the property of their respective owners. The information presented here is in summary form only and intended to provide broad knowledge of products offered. You should consult your physician before purchasing any product(s). Otto Bock disclaims any liability related from medical decisions made based on this article summary.